Phio Pharmaceuticals
PHIO
Phio Pharmaceuticals (PHIO) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $14.00 | Aug 26, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 | Feb 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 | Aug 15, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 | Jun 25, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $14.00 | Jun 5, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $4.00 | Apr 8, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $4.00 | Feb 19, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $4.00 | May 14, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $4.00 from $6.00 | Feb 6, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $6.00 | Aug 16, 2023 |
Frequently asked questions
What is the latest analyst rating on PHIO?
On Aug 26, 2026, HC Wainwright & Co. maintained Phio Pharmaceuticals at Buy with a price target of $14.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.